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Abstract
Background—Rates of routine human papillomavirus (HPV) vaccination of adolescent males in 
the U.S. are low. Leading health organizations advocate consistent and strong physician 
recommendations to improve HPV vaccine dissemination. This study describes the prevalence and 
correlates of consistent and strong physician recommendations for HPV vaccination of adolescent 
males.
Methods—We surveyed pediatric and family medicine physicians in Florida about their HPV 
vaccine recommendations for male vaccine-eligible age groups (11–12, 13–17, 18–21 years). 
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Descriptive statistics compared consistency and strength of HPV recommendations across age 
groups. Multivariable logistic regression examined factors associated with of consistent and strong 
recommendations for 11–12 year olds.
Results—We received 367 completed surveys (51% response rate). Physicians most often 
consistently and strongly recommended HPV vaccine to males 13–17 (39%) compared to ages 11–
12 (31%) and 18–21 (31%). Consistent and strong recommendation for 11–12 year old males was 
more likely to be delivered by Vaccine for Children providers and less likely among physicians 
who reported more personal barriers to vaccination, particularly concerns about vaccine safety, 
concerns about adding vaccines to the vaccine schedule, and difficulty remembering to discuss 
HPV vaccination.
Conclusion—Physicians’ current consistency and strength of HPV vaccine recommendations do 
not align with national recommendations. Interventions to improve HPV vaccine 
recommendations must also consider the influence of physicians’ personal barriers to HPV 
vaccine delivery.
Impact—As one of the first studies to examine both consistency and strength of physicians’ HPV 
vaccine recommendations for males, our findings can inform future interventions focused on 
facilitating physicians’ recommendations.
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Introduction
In 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine 
human papillomavirus (HPV) vaccination of all males ages 11–12 years, catch-up 
vaccination for males ages 13–21 years, and vaccination for men who have sex with men 
ages 22–26.(1) The ACIP updated this recommendation in 2015 to include the recently 
licensed 9-valent HPV vaccine.(2) Yet, HPV vaccination uptake among adolescent males 
nationally and in Florida is modest. In 2014, HPV vaccine initiation rates among males both 
in Florida and nationally was ~41%; coverage with ≥3 dose among males ages 13–17 was 
22% in the United States (US) and 17.5% in Florida (range: 9% in Alabama to 43% in 
Rhode Island).(3) Available data suggest rates are even lower for 11–12 year olds, who 
constitute the target age group for vaccination.(4) Florida has among the nation’s highest 
rates of HPV-related diseases in males, including the 5th highest rate of anal cancer.(5) Given 
the established efficacy of preventing HPV infections that cause anal and penile cancer,(6, 7) 
HPV vaccination has tremendous potential for primary prevention,(8, 9) particularly for 
males from racial/ethnic and sexual minority groups disproportionately affected by HPV-
related diseases.(10–12)
The Centers for Disease Control and Prevention (CDC)(13) and the President’s Cancer 
Panel(14) advocate consistent and strong physician recommendations, particularly for the 
target age group of 11–12 year old adolescents, as a primary approach to improving HPV 
vaccine dissemination. Yet, relatively little research has examined the consistency and 
strength of physicians’ HPV vaccine recommendations specific to males following the 
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ACIP’s recommendation for routine vaccination. Regarding consistency, results from a 
statewide survey of pediatricians, family physicians, and nurse practitioners in Minnesota 
showed that about 46% of providers routinely recommended HPV vaccine for boys ages 11–
12 years.(15) A national survey found that 61% of pediatricians and family physicians 
started routinely recommending HPV vaccine for males at or before age 12. For strength, a 
national survey of pediatricians and family physicians found that 52% of pediatricians and 
41% of family physicians strongly recommend HPV vaccine for 11–12 year old males,(16) 
compared to 64% of pediatricians and 50% of family physicians in Hawaii.(17) To our 
knowledge, only one study has examined both consistency and strength of physicians’ HPV 
vaccine recommendations as part of a larger recommendation quality measure, but did not 
focus solely on male patients.(16) Because available literature demonstrates a disparity in 
recommendation practices such that fewer physicians report consistent and strong HPV 
vaccine recommendations for males compared to females,(15–18) it is important to further 
explore factors associated with physicians’ HPV vaccine recommendations for males.
Understanding recommendation practices and factors associated with those practices in a 
state with low vaccine uptake is essential to designing and implementing interventions to 
improve physicians’ HPV vaccine recommendations. The medical encounter presents 
competing demands that pull physicians in many directions and influence how they 
recommend/provide preventive services during patient encounters. These ideas serve as the 
basis for the Competing Demands Model (CDM),(19) originally developed to understand 
delivery of clinical preventive services in the primary care setting. The CDM proposes that 
physician (e.g., specialty, attitudes), patient (e.g., knowledge, attitudes), and practice 
environment (e.g., setting, location) factors influence physicians’ delivery of preventive 
health services. While several of these CDM factors have been explored by our group(20–
22) and others(23), few have delved into vaccine-specific factors within the practice 
environment such as the presence of a vaccine coordinator and use of specific types of 
reminder systems for series initiation and completion.
This study examines the prevalence of physician recommendation of HPV vaccination to 
vaccine-eligible males ages 11–12, 13–17, and 18–21 in Florida. Given ACIP 
recommendations emphasize routine vaccination targeting 11–12 year olds and an emphasis 
on multilevel approaches to improving HPV vaccination rates,(24) we assessed examined 
physician reported factors relevant to the physician and practice (both general and vaccine 
specific) domains of the CDM as correlates of HPV vaccine recommendation for this age 
group.
Materials and Methods
Recruitment
Physicians were recruited from the American Medical Association (AMA) Physician 
Masterfile, a database of all licensed U.S. physicians.(25) Our initial sampling frame 
excluded those who: 1) were trainees, 2) locum tenens, 3) reported their major professional 
activity as non-patient care, 4) were ≥65 years of age, as the AMA Masterfile has been 
shown to have a significant lag in updating retired physicians,(26) and 5) listed a post office 
box for their address (precluding use of FedEx mailing). Florida pediatric and family 
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medicine (FM) physicians were sampled based on their proportional representation in the 
Florida physician primary care workforce and randomly selected from the AMA Masterfile 
(n=770). We selected only 1 physician per group practice. Informed by Dillman’s Tailored 
Design Method,(27) pre-notice postcards were mailed in May 2014, followed by the first 
survey mailing in June 2014. Although the survey itself was anonymous, we limited 
subsequent mailings by using a postage paid postcard that was included with every survey 
mailing where physicians were asked to provide their name, address, and select from options 
including: (1) I have completed and sent the survey back in the prepaid envelope or (2) I do 
not wish to participate and have returned the blank survey and the $25 incentive. Follow up 
mailings were sent to all those from whom we did not receive a completed postcard through 
August 2014. Participating physicians received a $25 cash incentive.
Of the 770 surveys mailed, 367 were received. After accounting for undeliverable surveys 
(n=36) and ineligible respondents (n=10), the overall response rate was 51% (367/724). We 
excluded 12 participants who reported not seeing male patients ages 9–26, for an analytic 
sample size of 355.
Instrument
Where possible, we used previous survey items to assess HPV vaccination recommendation;
(20, 28–34) new items were created to measure constructs not assessed in previous studies 
are noted below. The final 49-item survey assessed three domains relevant to the CDM: 
physician characteristics, physician reported general and vaccine specific practice 
characteristics.
Physician reported characteristics were perceived personal and parental barriers related to 
HPV vaccination, HPV-related knowledge, and demographic characteristics. Sixteen items 
assessed physician-reported barriers to immunizing male patients against HPV. Perceived 
parental HPV vaccination barriers for 9- to 17-year-old male patients were measured using 
14 items. Response options for physician-reported and perceived parental barriers were on a 
4-point Likert scale (1=not a barrier at all to 4=a major barrier). Items were summed to 
create scores for perceived personal (range: 16–64; Cronbach’s alpha=0.88) and parental 
barriers (range: 14–56; Cronbach’s alpha=0.90). Lower scores indicated lower perceived 
barriers. Knowledge was measured using 9 items regarding HPV infection, disease, and 
vaccine guidelines for males. We built on previous surveys by creating new items to assess 
knowledge specific to guidelines and financial coverage for vaccinating males. One point 
was awarded for each correct response and correct responses were summed to create a 
knowledge score (range: 0–9).
Physician reported general practice characteristics included number of physicians in the 
practice, practice situation (single specialty, multispecialty, other), practice type (private, 
other), race/ethnic category of the majority of patients seen, whether the practice serves 
Medicaid patients, typical daily patient load, and practice location (urban, suburban, rural, 
other). Vaccine-specific practice characteristics were administration of HPV vaccine, 
Vaccines for Children (VFC) provider, strategies for remembering to discuss HPV vaccine 
with male patients, specific strategies to get patients into the office for the first and 
subsequent dose(s) of vaccine, total number of strategies used to get patients into the office 
Vadaparampil et al. Page 4
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
for the first and subsequent dose(s) of vaccine, and presence of an office vaccine 
coordinator. We created new survey items to assess whether other healthcare professionals 
(i.e., medical assistant, nurse, nurse practitioner, physician assistant) in the practice discuss 
and recommend HPV vaccine. The final survey can be obtained by emailing the 
corresponding author.
In addition to items evaluating domains relevant to CDM, our survey included new and 
previous items that assessed the context and content of vaccination recommendation.(35) 
New items also assessed provider’s acceptance and use of the Centers for Disease Control 
and Prevention messages and materials to support HPV vaccine recommendation for 
adolescent males(36) and intervention preferences.
The primary outcome variables were HPV vaccine recommendations to vaccine-eligible 
males ages 11–12, 13–17, and 18–21. Given that national guidelines call for consistent and 
strong recommendations, we assessed recommendation consistency and strength using two 
questions from prior studies.(33, 34) The first question asked providers to indicate how often 
they recommended HPV vaccination by age group: never/almost never (<10%), occasionally 
(10–39%), about half the time (40–59%), usually (60–90%), and always/almost always 
(>90%). Providers were also asked how strongly they recommended vaccination by age 
group: I recommend against; I make no recommendation for or against; I recommend, but 
not strongly; and I strongly recommend. In addition to reviewing these items individually, 
we created a composite variable to reflect that national guidelines call for both consistent 
and strong recommendations. We combined these two questions into one variable to 
compare those who reported recommending vaccination consistently (always/almost always) 
and strongly to physicians who reported any other combination of responses.
Data analysis
Frequencies and percentages were calculated for independent and outcome variables. To 
reflect national guidelines for consistent and strong HPV vaccine recommendations targeted 
to adolescent males ages 11–12, we focused analyses on assessing correlates of 
recommendation for this age group. This was done in three steps. First, simple logistic 
regression models examined each correlate. Second, within each domain, significant 
univariate correlates were entered into a multivariable model. A backward elimination 
approach (significance level of stay = 0.05) was used to determine those correlates making 
relatively independent contributions to consistent and strong HPV vaccine recommendations 
for each domain. Significant correlates in the final model for each domain were then entered 
into a multivariable model using a backward elimination approach to generate a model of the 
relatively independent correlates across domains. Odds ratios (OR) and their 95% 
confidence intervals (CI) were estimated in each model. All analyses used two-tailed tests 
with the significance level set at p < 0.05, and were performed using the SAS® 9.3 statistical 
software package (SAS Institute Inc., Cary, North Carolina).
Results
The sample was almost equally comprised of female (51.0%) and male (49.0%) physicians 
(Table 1), with an average age of 48.7 years (standard deviation [SD] = 9.0). Most were 
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White (67.7%) and non-Hispanic (75.1%). About half specialized in FM (49.9%) and had 
been practicing for ≥16 years (51.9%). HPV vaccine knowledge scores averaged 5.7 (SD = 
2.1; range: 0–9).
Physicians most often reported their practice had two physicians (49.9%), was single 
specialty (66.8%), private practice (67.2%), and in a suburban location (52.6%). Over one-
third (36.6%) reported seeing mostly patients from minority groups and about one-fifth 
(20.2%) reported no definable majority. The majority reported seeing Medicaid patients 
either along with other types of insurance (67.6%) or solely (1.9%). Almost half (44.5%) 
saw 20–29 patients daily. The majority reported administering HPV vaccine in their practice 
(68.8%) and nearly half were VFC providers (45.9%). Over half did not use a strategy to get 
patients in for the first dose of HPV vaccine (52.5%), but most used ≥1 strategies to get 
patients vaccinated with subsequent doses (84.3%). Physicians reported using flagging 
charts (16.6%), automatic prompts (22.2%), and electronic queries (13.6%) to remind 
themselves to discuss HPV vaccine. About three-fourths reported having a vaccine 
coordinator (72.2%).
The anonymous nature of the survey precludes examining the degree to which survey 
responders and non-responders were similar on demographic and practice characteristics. 
However, we were able to compare responding physicians to the population of physicians in 
Florida meeting our study eligibility criteria on characteristics including age, sex, and 
clinical specialty. We found no statistically significant difference between responding 
physicians and the larger population of Florida physicians for age, sex, and clinical specialty 
(all p > .05).
Compared to older adolescent groups, a lower proportion of physicians reported consistently 
(34.8%), strongly (42.9%), and both consistently and strongly (30.6%) recommending HPV 
vaccine to the 11–12 year old group (Figure 1). As shown in Figures 2 and 3, physicians’ 
mean perceived personal barriers score was 30.3 (SD = 9.6; range: 16–61) and the mean 
perceived parental barriers score was 37.0 (SD = 8.9; range: 14–56). As can be seen in Table 
2, consistent and strong HPV vaccine recommendation for 11–12 year olds was associated 
with the following variables in univariate analyses: physician gender, specialty, personal 
barriers, HPV knowledge, patient race, Medicaid patients seen, practice location, and all 
vaccine-specific practice characteristics.
Within each domain (physician characteristics, general practice characteristics, and vaccine-
specific practice characteristics), a multivariable analysis using a backward stepwise 
approach was applied starting with the significant univariate correlates in each group (Table 
2). Two physician characteristics were significantly associated with consistent and strong 
recommendations: pediatric specialty (AOR = 2.55; 95% CI, 1.38–4.71) and fewer (or 
lower) physician reported barriers (AOR = 0.94; 95% CI, 0.90–0.97). The lone general 
practice characteristic was serving Medicaid patients (OR = 3.11; 95% CI, 1.48–6.53). The 
lone vaccine-specific characteristic was being a VFC provider (OR = 6.48; 95% CI, 3.47–
12.1).
Vadaparampil et al. Page 6
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A multivariable analysis was performed using backward stepwise regression starting with 
the significant correlates in the domain-specific multivariable models (Table 2). In the final 
multivariable model, fewer (or lower) physician barriers (AOR = 0.91; 95% CI, 0.88–0.94) 
and being a VFC provider (AOR = 5.43; 95% CI, 2.80–10.55) were statistically significant 
correlates of HPV vaccine recommendation in 11–12 year olds.
Given that that the total score for physician barriers was inversely associated with strong and 
consistent HPV vaccine recommendations, we performed a posthoc analysis to explore each 
of the 16 physician barriers as a correlate. The results of these analyses are presented in 
Table 3. Alpha was adjusted to 0.0031 (=.05/16) for univariable analyses and alpha=.05 for 
multivariable analyses. Ten of the 16 individual barriers were significant correlates (left 
column). Only one of these ten barriers was significant in a multivariable model (middle 
column), highlighting the positive correlation among the individual barriers which is also 
exhibited in the relative high Cronbach’s alpha (0.88). The barriers that remained 
statistically significant following a backward stepwise approach (right column) were 
physician concern about vaccine safety, concern about adding another vaccine to the 
schedule, and remembering to discuss the vaccine.
Discussion
Recent efforts to improve physician recommendation for HPV vaccination have focused on 
two critical components. First, the recommendation should be consistent for all adolescent 
males and females, particularly the 11–12 year old age group for which routine vaccination 
is recommended. This is clearly demonstrated by the 2011(1) and 2015(2) ACIP guidelines 
endorsed by all professional medical societies that provide preventive care to adolescent 
males. Second, as noted in the President’s Cancer Panel Report focused on HPV 
vaccination, the recommendation must be strong.(24) Our study demonstrates that, despite 
available guidelines, a minority of physicians indicated that they consistently (35%), 
strongly (43%), and both consistently and strongly (31%) recommend HPV vaccination to 
the target 11–12 year old adolescent male age group. While our study focused on 
recommendation for males, studies that have examined differences in recommendation by 
gender highlight a marked disparity in vaccine recommendations between boys and girls.
(15–18) Without immediate and targeted intervention, the nation is unlikely to achieve 
Healthy People 2020 goal of 80% of 13–15 year old adolescents receiving the entire three 
dose HPV vaccine series.(37)
Relative to physicians reporting high HPV vaccination barriers, those reporting low barriers 
were more likely to consistently and strongly recommend vaccination. This finding aligns 
with previous research reporting that barriers to vaccination were associated with physicians 
not strongly recommending HPV vaccination to females aged 11–12 years(38) or offering 
the vaccine at all.(39) Thus, one approach to improving vaccination recommendation may be 
to reduce provider barriers.
Barriers significantly associated with recommendation in the current study included 
concerns about vaccine safety, adding another vaccine to the schedule, and remembering to 
discuss vaccination. Interestingly, a systematic review of provider communication about 
Vadaparampil et al. Page 7
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
HPV vaccination identified no studies demonstrating an association between providers’ 
perceptions of HPV vaccine safety and their recommendation behaviors.(40) However, our 
survey took place more recently than those included in the systematic review and may reflect 
the cumulative impact of media coverage that presents HPV vaccination in a controversial 
political context and as a vaccine for females.(41) Thus, providers responding to our survey 
may be less aware of the safety of HPV vaccine for males. The ACIP recommendations for 
universal male HPV vaccination also coincided with political debates surrounding the 
vaccine during the 2012 presidential campaign.(42) Additionally, physician concerns about 
safety may be influenced by events such as the Japanese government’s decision in June 2013 
to stop proactive recommendation of HPV vaccine due to safety concerns.(43, 44)
Physicians in our study also expressed concerns about adding another vaccine to the 
schedule. This concern has been documented in the context of adding a new vaccine to the 
early childhood immunization schedule (45) and HPV vaccination (20, 23). This finding is 
particularly concerning and should be addressed when suggesting that providers deliver a 
bundled recommendation that includes HPV alongside Tetanus, diphtheria, & acellular 
pertussis (Tdap) and meningococcal vaccines, which are also recommended at ages 11–12 
for boys and girls.(46)
Difficulty remembering to discuss HPV vaccine with males was the third barrier associated 
with recommendation for males. Given the strong correlation between provider 
recommendation and HPV vaccine uptake in males,(47) providers forgetting to discuss the 
vaccine offers one possible explanation for lower series initiation rates in males compared to 
females, despite the 2011 ACIP recommendation for routine vaccination in age eligible 
males.(1) The President’s Cancer Panel recommends use of provider reminders to reduce 
missed opportunities for HPV vaccination.(24) Almost two thirds of respondents (67%) did 
not use any reminders to discuss HPV vaccination with patients and approximately half 
(44%) used no strategy to get patients into the office for the first dose. In our study, we 
specifically examined the manual and electronic strategies for remembering to discuss HPV 
vaccine with male patients, and specific strategies to get patients into the office for the first 
and subsequent dose(s) of vaccine. Although our study found no association between use of 
reminders and recommendation, it is possible that the relatively small number of those using 
these approaches precluded detection of a statistically significant association.
One study found that clinics using an electronic health record based point of care reminder 
system targeting both clinicians and patients resulted in significantly more young women 
initiating and completing the HPV vaccine series in a timely fashion. The authors suggested 
that this combined strategy may have supported the creation of a common agenda that 
facilitates HPV vaccine series initiation.(48) A recent literature review of interventions to 
increase HPV vaccination rates suggested that there was sufficient evidence to support the 
use of Community Preventive Task Force recommendations related to client reminder and 
recall systems as well as provider assessment and feedback.(49) Thus, future interventions 
may benefit from considering point-of-care reminders that simultaneously prompt 
physicians and patients to discuss HPV vaccination.(50)
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In our study, physicians who participated in the VFC program were more likely to 
recommend vaccination than those not participating. VFC-enrolled providers administer to 
Medicaid-eligible, uninsured, or American Indian or Alaska Native children younger than 
age 19.(51, 52) VFC also serves underinsured children in limited public settings (e.g., 
federally qualified health centers). Davis et al.(53) found that physician recommendation for 
pneumococcal conjugate vaccine (PCV7) was associated with the child’s insurance coverage 
for the vaccine and state VFC policy. Another study demonstrated that patients of VFC 
providers were 59% more likely to be up-to-date with early childhood vaccines than patients 
of non-VFC providers.(54) However, it is unclear why these providers are more likely to 
recommend vaccination. It is possible that participating in the VFC program reduces 
physicians’ up-front costs by offering free vaccines for VFC-eligible children.(55) Providers 
also do not have to send patients elsewhere to receive vaccines. It is also possible that VFC 
providers also represent those who are more supportive of vaccines overall and willing to 
offer in-office vaccination in their practice setting. Future qualitative interviews with VFC 
and non-VFC providers may help to further explore these possible explanations.
To our knowledge, our study is among the first to focus specifically on physicians’ HPV 
vaccine recommendations for males after the ACIP guidelines for routine vaccination of 
adolescent males. Additionally, this is among the first observational studies to describe the 
current use of electronic and manual reminders for both physicians and patients related to 
HPV vaccination. This study has several notable strengths, including a statewide sample of 
primary care providers and an examination of physicians’ recommendation with respect to 
both consistency and strength. There are also limitations. Our cross sectional survey design 
precluded our ability to make causal inferences about variables significantly associated with 
recommendation of HPV vaccination. Additionally, we surveyed physicians from a single 
state; although this design limits our ability to generalize findings to physicians practicing in 
our states, it allowed us to focus on HPV vaccine recommendations in a state with relatively 
high rates of HPV-related disease in males. We provided quantitative “anchors” for our 
questions regarding consistency but not strength of vaccine recommendation. Physicians 
may vary in their interpretation of a strong recommendation. Physicians may have reported 
socially desirable responses regarding practice behaviors; however, the anonymity of the 
survey likely reduced this bias. Physicians most in favor of HPV vaccination may have 
completed the survey, possibly providing an overestimate of the proportion that consistently 
and strongly recommend HPV vaccination. In our sample, 31% of providers reported HPV 
vaccine currently is not administered to males in their clinical setting. However, we did not 
include any follow up questions as to why they currently do not administer. It is possible that 
they simply do not vaccinate in their office. Although less likely, they may specifically not 
offer HPV vaccination for males. Finally, our study was limited to physicians, although other 
healthcare providers may recommend HPV vaccination. Thus, study of groups delivering 
care to adolescent males, such as nurses, medical assistants, and physician assistants, is 
warranted.
Physician recommendation is key to increasing HPV vaccine coverage; yet, physicians’ 
current HPV vaccine recommendations do not align with national guidelines and U.S. health 
organization recommendations. Interventions are needed to support HPV vaccine 
recommendation consistency and strength. Our research and others’ suggest these 
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interventions also should include education about and strategies as well as policy level 
interventions to address financial barriers to HPV vaccination. Current efforts to bolster 
physician recommendation have largely been focused on communication skills and office-
based strategies to increase HPV vaccination rates. For example, the CDC’s You are the Key 
Campaign(56) largely provides patient and provider educational materials and provider 
communication strategies. More recently, the American Academy of Pediatrics HPV 
Champion Toolkit(57) has extended resources provided in the You are the Key Campaign to 
include tools to facilitate change at the practice level (e.g., electronic health record-based 
reminder recalls). Our survey found that Florida physicians’ barriers to consistently and 
strongly recommending HPV vaccine were related to concerns about vaccine safety, 
concerns about adding vaccines to the vaccine schedule, and difficulty remembering to 
discuss HPV vaccination. These findings suggest that future interventions should include 
components to address these issues at the physician and practice level. By addressing 
physicians’ challenges and supporting their HPV vaccine recommendations to their male 
patients, we can increase HPV vaccine coverage in Florida and reduce HPV-related disease.
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SD standard deviation
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Figure 1. Percentage of Physicians Reporting Consistent and Strong Recommendation of HPV 
Vaccination (n=355)
Note. The number of patients seen differs by patient age group and category: 11–12 years, n 
ranges from 284–305; 13–17 years, n = 303–318; 18–21 years, n = 312–321.
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Figure 2. Physicians’ Barriers when Immunizing Male Patients against HPV
Abbreviations: STIs, sexually transmitted infections; VFC, Vaccines for Children
Notes: N values differ for each barrier due to missing data. Missing data for each item 
ranged from 8 to 23 participants.
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Figure 3. Physicians’ Perceptions of Parental Barriers when Immunizing Male Patients against 
HPV
Abbreviations: STIs, sexually transmitted infections
Notes: Number of respondents ranged from 261 to 263. Many non-responders see only 
patients 18 years or older.
Vadaparampil et al. Page 16
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Vadaparampil et al. Page 17
Table 1
Sample characteristics (N=355)
Physician characteristics n (%) Mean (SD)
Gender
 Female 178 (51.0)
 Male 171 (49.0)
Age 48.7 (9.0)
 30–39   64 (18.3)
 40–49 124 (35.5)
 ≥50 161 (46.1)
Race
 White/Caucasian 233 (67.7)
 Black/African American  22 (6.4)
 Asian   38 (11.1)
 Other   51 (14.8)
Ethnicity
 Hispanic   86 (24.9)
 Non-Hispanic 259 (75.1)
Years practicing
 10 or fewer 100 (29.3)
 11–15   64 (18.8)
 16 or more 177 (51.9)
Clinical specialty
 Pediatrics 155 (44.4)
 Family Medicine 174 (49.9)
 Othera  20 (5.7)
HPV knowledge (range 0–9)   5.7 (2.1)
Physician barriers score (range 16–61)b 30.3 (9.6)
Parental barriers score (range 14–56)b 37.0 (8.9)
General practice characteristics n (%) Mean (SD)
Number of physicians in practice
 1 100 (28.7)
 2 174 (49.9)
 6–15   46 (13.2)
 16 or more  29 (8.3)
Practice situation
 Single specialty 233 (66.8)
 Multi-specialty   91 (26.1)
 Other  25 (7.2)
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Physician characteristics n (%) Mean (SD)
Practice type
 Private practice office 229 (67.2)
 Other 112 (32.8)
Practice location
 Urban 129 (37.7)
 Suburban 180 (52.6)
 Rural/Other  33 (9.7)
Race of majority of patients seen
 White, non-Hispanic 143 (43.2)
 Minority group(s) 121 (36.6)
 No definable majorityc   67 (20.2)
Medicaid patients served
 Medicaid, only   6 (1.9)
 Medicaid and others 215 (67.6)
 No Medicaid   97 (30.5)
Typical daily patient load
 Less than 15   41 (11.8)
 15–19   96 (27.6)
 20–29 155 (44.5)
 30 or more   56 (16.1)
Vaccine specific characteristics n (%) Mean (SD)
Administer HPV vaccine
 Yes 242 (68.8)
 No 110 (31.2)
VFC provider
 Yes 162 (45.9)
 No 156 (44.2)
 Do not know  35 (9.9)
Strategies used for remembering to discuss HPV vaccine with eligible patients
  Flag charts   55 (15.5)
  Use automated electronic medical record prompts   74 (20.9)
  Perform periodic electronic queries to identify vaccine-eligible patients   45 (12.7)
 Used any of the 3 strategies 111 (31.3)
Strategies to get patients into office for first dose of HPV vaccine
  Send reminder regarding preventive visit   75 (21.3)
  Send letter or call patients specifically for HPV vaccine   37 (10.4)
  Place reminder flag/tag in patients’ medical record  31 (8.7)
  Use a computerized immunization database/registry to track when first dose is due   47 (13.2)
  Use some other strategy  18 (5.1)
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Physician characteristics n (%) Mean (SD)
  Do not use any strategy 156 (43.9)
  Not applicable: Do not administer vaccine   60 (16.9)
Strategies to get patients into office for second and third dose of HPV vaccine
  Record does due date on card kept by patient   75 (21.3)
  Send letter or call patients specifically for HPV vaccine   62 (17.5)
  Place reminder flag/tag in patients’ medical record   43 (12.1)
  Schedule patient for next dose during office visit 189 (53.2)
  Use a computerized immunization database/registry to track when first dose is due   49 (13.8)
  Use some other strategy  20 (5.6)
  Do not use any strategy   43 (12.1)
  Not applicable: Do not administer vaccine   62 (17.5)
Number of strategies used for first dose of vaccined
 None 140 (50.0)
 1   89 (31.8)
 2 or more   51 (18.2)
Number of strategies used for second and third doses of vaccinee
 None   38 (13.3)
 1 134 (47.0)
 2 or more 113 (39.7)
Other HCP in practice recommends HPV vaccine
 Yes 153 (43.7)
 No 197 (56.3)
Other HCP in practice discusses HPV vaccine
 Yes 148 (42.4)
 No 201 (57.6)
Vaccination coordinator in practicef
 Yes 252 (72.2)
 No   88 (25.2)
 Do not know   9 (2.6)
aOther clinical specialty includes Urgent Care, Acute Care, Internal Medicine, Hospice, Geriatrics, General Physician, Primary Care, Emergency 
Room.
b
Response options for physician-reported and perceived parental barriers were on a 4-point Likert scale (1=not a barrier at all to 4=a major barrier). 
Items were summed to create scores for perceived personal (range: 16–64) and parental barriers (range: 14–56). Lower scores indicated lower 
perceived barriers.
c
There was no racial/ethnic group that comprised the majority of their patients.
dStrategies used to get patients into the office for the first dose of HPV vaccine for those who administer vaccine.
eStrategies used to get patients into the office for the second and third doses of HPV vaccine for those who administer vaccine.
fQuestion was asked as follows: “Is there a vaccine coordinator in your office (i.e., someone responsible for purchasing, receiving and storing 
vaccine shipments, maintaining vaccine inventory, training staff members on vaccine administration, etc.)?”
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Table 2
Predictors of Consistent and Strong Recommendation to 11–12 Year Olds for Physicians at Practices that 
Administer HPV Vaccine (N=208)
OR [95% CI]a
Multivariable
AOR [95% CI]b
Multivariable
AOR [95% CI]c
Physician Characteristics
 Female gender 1.45 [0.82, 2.57] – –
 Age 0.99 [0.96, 1.02] – –
 White, non-Hispanic race/ethnicity 1.00 [0.80, 1.27] – –
 Years practicing 0.99 [0.96, 1.03] – –
 Pediatric clinical specialty 2.54 [1.36, 4.75] 0.74 [0.21, 2.67] –
 Physician barriers score 0.92 [0.89, 0.96] 0.94 [0.89, 1.00] 0.93 [0.89, 0.97]
 Perceived parental barriers score 0.96 [0.93, 1.00] 0.98 [0.93, 1.03] –
 HPV knowledge 1.24 [1.06, 1.45] 1.08 [0.88, 1.34] –
Practice Characteristics: General
 Number of physicians in practice 0.89 [0.64, 1.24] – –
 Single specialty practice 0.54 [0.29, 0.99] 0.45 [0.18, 1.13] –
 Private practice office 0.49 [0.26, 0.90] 0.69 [0.25, 1.89] 0.45 [0.22, 0.92]
 Majority of patients non-Hispanic White 0.42 [0.23, 0.78] 0.69 [0.31, 1.57] –
 Medicaid patients seen 2.89 [1.32, 6.28] 0.58 [0.17, 2.34] –
 Typical number of patients/day 1.01 [0.73, 1.40] – –
 Urban practice location 2.08 [1.16, 3.71] 2.57 [1.17, 5.64] 2.08 [1.08, 4.02]
Practice Characteristics: Vaccination
 VFC provider 3.74 [1.87, 7.47] 5.73 [1.31, 25.1] 3.80 [1.70, 8.54]
 Flag charts of vaccine eligible patients 1.94 [0.99, 3.81] – –
 Use automated electronic medical record prompts* 1.59 [0.84, 3.01] – –
  Perform periodic electronic queries to identify vaccine-eligible patients* 1.78 [0.86, 3.70] – –
 Other HCP recommends vaccination 1.24 [0.69, 2.25] – –
 Other HCP discusses vaccination 1.28 [0.69, 2.35] – –
 Strategies for 1st vaccination: None 1.30 [0.92, 1.87] – –
 Strategies for 2nd vaccination: None 1.19 [0.77, 1.84] – –
 Vaccination coordinator 3.06 [1.10, 8.52] 1.09 [0.28, 4.33] –
Abbreviations: CI, confidence interval; HCP, healthcare provider; HPV, human papillomavirus; OR, odds ratio; AOR, adjusted odd ratio; VFC, 
Vaccines for Children.
Notes: Bold ORs and CIs are statistically significant. For vaccination subset, the 5 variables not applied to the multivariable analysis were excluded 
due to high covariation with one or more variables that were included.
*
More than 10% of the data were missing for this predictor.
aSimple logistic regression model examined association between individual predictor and outcome variable.
b
Logistic regression model with all significant individual predictors. Sample size is 162.
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c
Final model following backward stepwise regression starting with all significant individual predictors. Sample size is 193.
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Table 3
Physician Barriers as Predictors of Consistent and Strong Recommendation of HPV Vaccine to 11–12 Year 
Olds
Physician Barrier
Univariate
OR [95% CI]*
Multivariable
AOR [95% CI]a
Multivariable
AOR [95% CI]b
Concerns about vaccine safety 0.32 [0.18, 0.56] 0.55 [0.27, 1.12] 0.47 [0.25, 0.86]
Concerns about vaccine efficacy 0.37 [0.22, 0.61] 0.90 [0.45, 1.80] –
Discussing sex 0.41 [0.22, 0.75] – –
Riskier sex behaviors 0.65 [0.42, 1.00] – –
Adding another vaccine to schedule 0.35 [0.22, 0.56] 0.65 [0.38, 1.13] 0.57 [0.34, 0.95]
Up-front cost 0.52 [0.40, 0.69] 0.84 [0.50, 1.41] –
Insufficient reimbursement 0.55 [0.43, 0.71] 0.80 [0.44, 1.46] –
Insufficient insurance coverage 0.63 [0.50, 0.80] 1.22 [0.71, 2.09] –
VFC program does not cover males >age 18 0.86 [0.70, 1.07] – –
Determining insurance coverage 0.62 [0.49, 0.79] 1.11 [0.71, 1.74] –
Vaccine expiring before use 0.44 [0.32, 0.62] 0.78 [0.49, 1.25] –
Insufficient time to discuss 0.37 [0.24, 0.55] 0.86 [0.50, 1.45] –
Remember to discuss 0.28 [0.18, 0.45] 0.49 [0.29, 0.84] 0.40 [0.25, 0.64]
Will not complete the series 0.64 [0.48, 0.86] – –
Not required by schools 1.01 [0.80, 1.28] – –
Rarely see adolescent males 0.69 [0.53, 0.90] – –
Abbreviations: CI, confidence interval; OR, odds ratio; AOR, adjusted odd ratio; VFC, Vaccines for Children.
Notes: Bold ORs and CIs represents statistical significance with alpha=.05/16=.0031 for univariate analyses and alpha=.05 for multivariable 
analyses.
*OR with CI from simple logistic regression model for each physician barrier item.
a
Multivariable model with all statistically significant variables from univariate analysis.
b
Multivariable model following backward stepwise regression starting with all statistically significant variables from univariate analysis.
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